Physician profile
Joanne Mazzarelli
NPI 1255495495
$1,431.23
in general payments reported to CMS, 2019-2025
17 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $73.32 · 2021: $104 · 2022: $286 · 2023: $257 · 2024: $284 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $326.63 | 2019-2025 | |
| Pfizer INC. | $219.41 | 2019-2023 | |
| Atricure, INC. | $204.93 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.60 | 2019-2025 | Lifevest |
| Amgen INC. | $162.37 | 2019-2024 | Repatha |
| Philips North America LLC | $104.66 | 2022-2025 | Mcot, Extended Holter, (5050) Extended Holter |
| Janssen Pharmaceuticals, INC | $40.64 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.93 | 2019-2023 | Eliquis |
| Kiniksa Pharmaceuticals, LTD. | $29.48 | 2022-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $27.88 | 2021-2022 | |
| Cvrx, INC. | $20.95 | 2025 | Barostim Neo System |
| Novo Nordisk INC | $19.58 | 2024 | Ozempic, Rybelsus |
| Medtronic, INC. | $18.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.92 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $16.24 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $14.66 | 2021 | |
| Boston Scientific Corporation | $13.98 | 2024 | Bodyguardian |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Mazzarelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.